Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Sarcoma 1CNS 1

Conditions

Glioma 2Glioblastoma 2Brain Neoplasms 2Wilms Tumor 1Sarcoma 1Rhabdomyosarcoma 1Retroperitoneal Neoplasms 1Peritoneal Neoplasms 1Ovarian Neoplasms 1Oligodendroglioma 1Neuroblastoma 1Neoplasms 1Gliosarcoma 1Gastrointestinal Neoplasms 1Desmoplastic Small Round Cell Tumor 1Astrocytoma 1Adrenocortical Carcinoma 1Adenocarcinoma 1

Interventions

Temozolomide 128Radiotherapy 85Bevacizumab 43Radiation 30Carmustine 29Irinotecan 22Erlotinib Hydrochloride 22Magnetic Resonance Spectroscopy 21Chemotherapy, Adjuvant 20Surgical Procedures, Operative 15O(6)-benzylguanine 15Carboplatin 14Radiotherapy, Intensity-Modulated 13Radiotherapy, Conformal 13sargramostim 12Sirolimus 9Imatinib Mesylate 9Filgrastim 9temsirolimus 8Thalidomide 8Sorafenib 8Radiosurgery 8Drug Therapy 8pembrolizumab 7motexafin gadolinium 7aldesleukin 7Vorinostat 7Procarbazine 7Gene Expression Profiling 7Gefitinib 7

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Gliosarcoma × Cytoreduction Surgical Procedures × CNS × Clear all
NCT01257594 2023-05-25

EGFR Inhibition Using Weekly Erlotinib for Recurrent Malignant Gliomas

Columbia University

Phase 1 Completed
22 enrolled
CNSSarcoma

Brain Neoplasms, Glioblastoma, Glioma, Gliosarcoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡